Martin Pharmaceuticals is dedicated to developing innovative therapies for patients suffering from rare diseases and complex medical conditions. Central to their approach is LIVANTRA, a drug that leverages the unique mechanism of action of trimetazidine to address critical health issues such as Acute-on-Chronic Liver Failure (ACLF) and Pulmonary Arterial Hypertension (PAH). For ACLF, LIVANTRA aims to reduce hepatocyte damage by shifting energy production from fatty acid oxidation to glucose oxidation, thereby decreasing the generation of harmful reactive oxygen species. Clinical data indicates that patients treated with LIVANTRA show significantly improved survival rates compared to standard care, highlighting its potential as a transformative therapy for those facing high mortality rates due to ACLF.

In the case of PAH, LIVANTRA targets the dysregulation of hypoxia-inducible factor 1 (HIF-1), which contributes to the disease's progression through excessive cell growth and reduced cell death. By inhibiting fatty acid oxidation and restoring the function of pyruvate dehydrogenase (PDH), LIVANTRA promotes a metabolic shift that favors energy production over cell proliferation. Non-clinical studies have demonstrated its effectiveness in reversing PAH in animal models, showcasing improvements in pulmonary arterial pressure and right ventricular function. With Orphan Drug Designation from the US FDA for both indications, Martin Pharmaceuticals is positioned to make significant strides in the treatment of these life-threatening conditions.

United States

At Martin Pharmaceuticals we are passionate about bringing life-changing advances to patients with rare diseases or challenging medical conditions. We aspire every day to make a real difference in people's lives, turning hope into answers.

Martin Pharmaceuticals

Company Details